| 88.1546 1.503 (1.73%) | 02-27 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 106.17 | 1-year : | 124.01 |
| Resists | First : | 90.9 | Second : | 106.17 |
| Pivot price | 86.34 |
|||
| Supports | First : | 85.01 | Second : | 81.37 |
| MAs | MA(5) : | 87.68 |
MA(20) : | 85.75 |
| MA(100) : | 78.33 |
MA(250) : | 61.02 |
|
| MACD | MACD : | 1.1  |
Signal : | 1 |
| %K %D | K(14,3) : | 62.8 |
D(3) : | 73.1 |
| RSI | RSI(14): 55.9 |
|||
| 52-week | High : | 90.9 | Low : | 33.49 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BIB ] has closed below upper band by 28.2%. Bollinger Bands are 32.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 86.81 - 87.39 | 87.39 - 87.87 |
| Low: | 83.22 - 83.78 | 83.78 - 84.25 |
| Close: | 85.8 - 86.74 | 86.74 - 87.52 |
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
Fri, 27 Feb 2026
BIB,PBE Options - Finviz
Tue, 24 Feb 2026
Palumbo Wealth Management LLC Buys New Stake in ProShares Ultra Nasdaq Biotechnology $BIB - MarketBeat
Sat, 14 Feb 2026
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Short Interest Down 27.9% in January - MarketBeat
Thu, 27 Nov 2025
BIB: A Tactical 2x Leveraged Biotech ETF (NASDAQ:BIB) - Seeking Alpha
Wed, 08 Nov 2023
ProShares Ultra NASDAQ Biotechnology ETF Stock Price, News, Quote & History - Investing News Network
Mon, 13 Dec 2021
atai Life Sciences Has Been Selected for Addition to the NASDAQ Biotechnology Index - Psychedelic Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|